,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,dividendRate,dividendYield,exDividendDate,payoutRatio,fiveYearAvgDividendYield,beta,trailingPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Robert A. Bradway', 'age': 59, 'title': 'Chairman, CEO & Pres', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 5487475, 'exercisedValue': 0, 'unexercisedValue': 43693576}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
1,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Peter H. Griffith', 'age': 63, 'title': 'Exec. VP & CFO', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 2574004, 'exercisedValue': 0, 'unexercisedValue': 245771}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
2,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Esteban  Santos', 'age': 54, 'title': 'Exec. VP of Operations', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 2521941, 'exercisedValue': 0, 'unexercisedValue': 8232750}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
3,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Dr. David M. Reese M.D.', 'age': 59, 'title': 'Exec. VP of R&D', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 2833393, 'exercisedValue': 0, 'unexercisedValue': 4932458}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
4,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Murdo  Gordon', 'age': 55, 'title': 'Exec. VP of Global Commercial Operations', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 2717562, 'exercisedValue': 0, 'unexercisedValue': 2469817}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
5,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Matthew C. Busch', 'age': 48, 'title': 'Chief Accounting Officer & VP of Fin.', 'yearBorn': 1974, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
6,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Mike  Zahigian', 'title': 'Sr. VP & Chief Information Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
7,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Arvind  Sood', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
8,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Mr. Jonathan P. Graham', 'age': 61, 'title': 'Exec. VP, Gen. Counsel & Sec.', 'yearBorn': 1961, 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
9,One Amgen Center Drive,Thousand Oaks,CA,91320-1799,United States,805 447 1000,805 447 1010,https://www.amgen.com,Drug Manufacturers—General,Healthcare,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",25200,"{'maxAge': 1, 'name': 'Ms. Nancy A. Grygiel', 'age': 54, 'title': 'Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,3,1,3,1693526400,1672444800,86400,2,246.6,245.8,245.0,247.2,246.6,245.8,245.0,247.2,7.96,0.0323,1692230400,0.5485,2.91,0.613762,17.715113,31,31,198,148,148,244.4,245.2,30000,30000,131050741760,199.8,293.8,4.9300556,226.456,226.5995,8.14,0.033008922,EUR,159416598528,0.30017,533756492,534900992,0.0023700001,0.79324996,12.677,19.32634,1672444800,1703980800,1688083200,0.047,7978999808,13.83,5.997,11.583,FRA,EQUITY,AMG.F,AMG.F,"AMGEN INC.  DL-,0001",Amgen Inc.,946882800,Europe/Berlin,CEST,7200000,245.0,none,34247999488,64.027,13763000320,61544001536,2.344,2.771,26581999616,907.595,49.732,0.08541001,1.73457,19917000000,10054124544,10800000000,0.049,0.059,0.74294996,0.51776004,0.38443002,USD,1.9193
